Results 81 to 90 of about 1,341 (183)
Incidence of Pneumocystis pneumonia in immunocompromised patients without human immunodeficiency virus on intravenous pentamidine prophylaxis: A systematic review and meta-analysis [PDF]
, 2023 BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is a first-line METHOD: We performed a systematic review and meta-analysis to estimate breakthrough PCP incidence and adverse reactions in HIV-uninfected immunocompromised patients receiving IVP ...
Ching, Patrick R, Chiu, Chia-Yu
core +2 more sources
Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field
Journal of Fungi, 2022 Acute lymphoblastic leukemia (ALL) patients comprise a highly immunocompromised group due to factors associated either with the treatment or the disease itself.
Christos Stafylidis +4 more
doaj +1 more source
Current management and new horizons in the treatment of oral candidiasis [PDF]
, 2023 Introduction: this study evaluated the effectiveness and perceptions of current treatments for oral candidiasis among dentists in the Salcedo canton.
Culqui Molina, Washington Paúl +3 more
core +2 more sources
Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects [PDF]
Clinical Pharmacology in Drug Development, 2019 AbstractRezafungin is a new echinocandin in development for treatment of candidemia and invasive candidiasis, and for prophylaxis of invasive fungal infections. Rezafungin is the first echinocandin to undergo definitive QT/QTc study. This phase 1, single‐center, randomized, double‐blind trial was conducted to assess effects of intravenous rezafungin vs
Shawn, Flanagan +4 more
openaire +2 more sources
Valutazione dei fattori di rischio per lo sviluppo di candidemia dopo interventi di cardiochirurgia maggiore [PDF]
, 2020 Background: Candida species are among the most frequent causative agents of healthcare-associated bloodstream infections, with mortality higher than 40% in critically ill patients. Specific populations of critically ill patients may present peculiar risk
Giacobbe, Daniele Roberto
core +1 more source
Frontiers in Pharmacology, 2022 Vulvovaginal candidiasis (VVC) is an infectious disease caused by Candida species, which affects millions of women worldwide every year. The resistance to available antifungal drugs for clinical treatment is a growing problem. The treatment of refractory
Zewei Chen +8 more
doaj +1 more source
The Lancet, 2022 BACKGROUND Rezafungin is a next-generation, once-a-week echinocandin in development for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp after ...
G. Thompson +136 more
semanticscholar +1 more source
Clinical Relevance and Characteristics of Aspergillus calidoustus and Other Aspergillus Species of Section Usti. [PDF]
, 2020 The Aspergilli of section Usti (group ustus) are represented by over 20 species, of which Aspergillus calidoustus is the most relevant human pathogen. Invasive aspergillosis (IA) caused by these fungi is rare but could represent an emerging issue among ...
Erard, V., Glampedakis, E., Lamoth, F.
core +1 more source
Hope on the horizon: Novel fungal treatments in development [PDF]
, 2020 The treatment of invasive fungal infections remains challenging due to limitations in currently available antifungal therapies including toxicity, interactions, restricted routes of administration, and drug resistance.
Coler-Reilly, Ariella +3 more
core +1 more source
Journal of Clinical Laboratory Analysis, Volume 39, Issue 21, November 2025.Antimicrobial resistance in Candida spp. is significant in individuals with HIV/AIDS infections, particularly in Iran. In this systematic review, a comprehensive systematic search was conducted to identify all the eligible studies between 1999 and 2024; the pooled resistance rates of Candida spp. against antimicrobial agents were estimated. The risk of
Aliasghar Fakhri‐Demeshghieh +8 more
wiley +1 more source